Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170443 · ClinicalTrials.gov registry record · Phase 2
Trivalent rHA Dose Escalation Study in Elderly Subjects
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 399
- Enrollment target
NCT00170443: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00170443 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 399 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00170443, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 399 participants
- Enrollment target
Study Summary
This study will compare the safety and immunogenicity of three different dose levels of an experimental recombinant influenza HA protein vaccine to a standard inactivated influenza vaccine in heallthy elderly subjects ages 65-80. Blood and nasal secretions for assessment of antibody responses will be obtained from all subjects prior to and one month after vaccination.
Interventions
- BIOLOGICAL rHAO Trivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
What the finished NCT00170443 record still lists
NCT00170443 is an interventional study that assigns participants to a tested intervention. The registered 399 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher).
The record links to 0 conditions, and to 1 intervention - of which rHAO Trivalent Influenza Vaccine is the first listed.
NCT00170443 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00170443 about?
NCT00170443 is a clinical study titled "Trivalent rHA Dose Escalation Study in Elderly Subjects". This study will compare the safety and immunogenicity of three different dose levels of an experimental recombinant influenza HA protein vaccine to a standard inactivated influenza vaccine in heallthy elderly subjects ages 65-80. Blood and nasal secretions for assessment of antibody responses will b...
What is the current status of trial NCT00170443?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 399 participants. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00170443?
The interventions under investigation include: rHAO Trivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00170443?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00170443's enrollment target sits among peer trials
399 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing